Star Therapeutics Raises $200M Series C+ Led by Janus Henderson Investors

Star Therapeutics Closes $200M Series C+

Star Therapeutics, a clinical-stage biotechnology company, has raised $200 million in a Series C+ round. Janus Henderson Investors led the financing.

What the Company Does

Star Therapeutics discovers and develops best-in-class antibodies intended to create life-changing therapies for patients, initially addressing unmet needs in hematology and immunology. The company applies its expertise in antibody innovation to interrogate areas of biology that have been overlooked and that have the potential to address multiple diseases with a single therapy.

Its lead program, VGA039, has the potential to be a universal hemostatic therapy that can treat numerous bleeding disorders, starting with von Willebrand disease (VWD). As a subcutaneously self-administered antibody therapy with convenient dosing, VGA039 has the potential to significantly reduce the treatment burden for patients.

Round Details

• Round type: Series C+
• Amount raised: $200,000,000 USD
• Funding date: October 23, 2026
• Lead investor: Janus Henderson Investors

Investor Syndicate

The round drew participation from a broad group of investors alongside the lead:

• Janus Henderson Investors (lead)
• RA Capital Management
• Agent Capital
• Redmile
• Cormorant Asset Management
• Sofinnova Investments
• OrbiMed
• Catalio Capital Management
• NYBC Ventures
• Soleus Capital
• New Leaf Venture Partners

Why It Matters for Acquisition Watchers

A $200 million Series C+ is a substantial late-stage financing for a clinical-stage antibody developer. The size of the round and the depth of the syndicate — spanning specialist life-sciences investors and crossover asset managers — signal continued institutional conviction in Star Therapeutics' antibody platform and its lead hematology program.

For strategic acquirers and investors tracking the hematology and immunology space, Star Therapeutics represents a company with a defined lead asset in VWD, a broader platform thesis around overlooked biology, and a fresh capital base that may support advancement of its pipeline. The Series C+ stage typically precedes later-stage value-inflection events, making the company a name to monitor as its programs mature.

Summary

Star Therapeutics has secured $200 million in a Series C+ round led by Janus Henderson Investors, with participation from RA Capital Management, Agent Capital, Redmile, Cormorant Asset Management, Sofinnova Investments, OrbiMed, Catalio Capital Management, NYBC Ventures, Soleus Capital, and New Leaf Venture Partners. The company is a clinical-stage antibody developer focused initially on hematology and immunology, with VGA039 as its lead program targeting von Willebrand disease and other bleeding disorders.